In this episode of EP Edge Journal Watch, Dr. Sharma reviews 11 important new studies shaping modern cardiac electrophysiology, arrhythmia care, and cardiovascular risk management. This March 2026 issue covers intravenous amiodarone in preexcited atrial fibrillation, the NURSECAT-AF randomized trial of nurse-led care after AF ablation, left bundle branch area antitachycardia pacing vs right ventricular ATP, varenicline for ventricular ectopy after myocardial infarction, and the first clinical experience with reversible electroporation mapping in atrial flutter.

The episode also examines abelacimab vs rivaroxaban in older patients with atrial fibrillation from AZALEA-TIMI 71, device-assisted vs standard Valsalva for supraventricular tachycardia, the first reported case of severe pulmonary vein stenosis after pulsed field ablation, and the COBRRA trial comparing apixaban vs rivaroxaban bleeding risk in acute venous thromboembolism. Rounding out the issue are a nationwide analysis of out-of-hospital cardiac arrest on the first weekday after holidays and why the 2026 ACC/AHA multisociety dyslipidemia guideline matters directly to EP clinicians.

This is a practical, evidence-focused review of where electrophysiology is heading: smarter AF care pathways, safer anticoagulation, better mapping, more physiologic pacing, improved SVT management, and a broader understanding of sudden cardiac risk.

Full newsletter: EP Edge Journal Watch with references and infographics is available on LinkedIn as well as on Substack, epedge.substack.com.

If you want, I can also make this into a shorter Transistor version, a more keyword-dense SEO version, or a more polished Apple/Spotify-style episode summary.

Folgen-ID: 1000756733344

GUID: 189bc95e-d6aa-453b-945d-8c3eba1d125d

Erscheinungs­datum: 23.3.2026, 10:30:00